Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 3Thoracic 2Gastrointestinal 2CNS 2Head & Neck 1Genitourinary 1Endocrine 1

Conditions

Urinary Bladder Neoplasms 1Thyroid Cancer, Papillary 1Pancreatic Neoplasms 1Melanoma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Astrocytoma 1

Interventions

Cisplatin 57pembrolizumab 54Cetuximab 43Radiotherapy 35Docetaxel 21Radiotherapy, Intensity-Modulated 20Paclitaxel 19Nivolumab 18Fluorouracil 18Carboplatin 17Radiation 14Radiosurgery 9Magnetic Resonance Spectroscopy 8Gemcitabine 8Everolimus 8Biopsy 8Surgical Procedures, Operative 7Oxaliplatin 7Cyclophosphamide 7durvalumab 6avelumab 6Erlotinib Hydrochloride 6Capecitabine 6spartalizumab 5epacadostat 5Surveys and Questionnaires 5Platinum 5Immunoglobulin G 5Gefitinib 5Dexamethasone 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × tovorafenib × Head & Neck × Clear all
NCT04985604 2025-10-02

Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors

Day One Biopharmaceuticals, Inc.

Phase 2 Terminated
23 enrolled 15 charts
CNSDermatologicEndocrineGastrointestinalGenitourinaryHead & NeckThoracic

Thyroid Cancer, Papillary, Astrocytoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡